Individualised antiplatelet therapy based on testing or genotyping: idea from the past or solution for the future

Chairpersons: G. Cayla, F.J. Neumann

Presentations available when logged in:

  • Impact of high platelet reactivity on clopidogrel after coronary stenting to the late lumen loss at long-term follow-up
  • How long does it take for clopidogrel to inhibit platelets in patients undergoing primary PCI for STEMI: the time course of platelet reactivity in...
  • Dual antiplatelet therapy monitoring in patients with unprotected left main stenting
  • Optimising P2Y12, receptor inhibition in ACS patients based on platelet function testing: impact of prasugrel vs high-dose clopidogrel
  • Individualising dual antiplatelet therapy after PCI: the IDEAL-PCI registry